6:48AM Seattle Genetics: phase IIb clinical trial of lintuzumab in older patients with acute myeloid leukemia did not meet its primary endpoint of extending overall survival; co will discontinue its development program for lintuzuma (SGEN) 12.72 :
Market Data 
Markets 
AI
